Smart Nuclide was created in Suzhou Industrial Park, received seed investment
Smart Nuclide announces the Completion of pre-Series A funding
The first rhTSh product (SNA001) in China receives IND approval from NMPA, Smart Nuclide launches phase I/II clinical trial in Zhongshan Hospital
Smart Nuclide launches Phase III clinical trial of SNA001, completes preliminary preparations for Investigational New Drug Application of SNA002
Smart Nuclide raises nearly CNY 100.0 M in Series B round, granted the “National Science and Technology Major Project for Novel Drug Development Unit”. Smart Nuclide announces the establishment of Radiopharmaceutical Collaborative Innovation Center with Soochow University
Smart Nuclide raises nearly CNY 100.0 M in Series C round, SNA001 completes phase III clinical trial. Smart Nuclide announces the plan to start Investigational New Drug Application (IND) file of SNA002 in the U.S. and China, SNA006 starts investigator-initiated trials (IIT)
SNA001 files the Biologics License Application (BLA) to Center For Drug Evaluation (CDE), SNA002 starts investigator-initiated trials (IIT), receives U.S. FDA Clearance of Clinical Trial, will soon start the clinical trial after the Clearance from the CDE. Smart Nuclide announces the construction of radioactive antibody-drug conjugate GMP manufacturing facility, expected to be used in late 2022
智核生物